Global Pulse

分类： health

  • Dubai pioneers global Parkinson’s Ramadan guidelines, uniting 25 nations

    Dubai pioneers global Parkinson’s Ramadan guidelines, uniting 25 nations

    In a landmark healthcare initiative, Dubai has unveiled the world’s first international guidelines for Parkinson’s patients observing Ramadan fasting. The pioneering framework was officially launched under the patronage of Sheikh Faisal bin Obaid Al Maktoum at the Mohammed Bin Rashid Library, marking a significant advancement in culturally-sensitive neurological care.

    The groundbreaking guidelines emerged from an unprecedented global collaboration spearheaded by King’s Parkinson’s Centre of Excellence in partnership with Parkinson’s UAE. The initiative united over 350 patients, caregivers, and leading medical experts from 25 nations across the Middle East, Europe, Asia, and Australasia, both in-person and virtually.

    Parkinson’s disease, recognized as the world’s second most common neurodegenerative disorder, affects approximately 2% of individuals over age 60. The guidelines address growing clinical concerns regarding young-onset Parkinson’s cases within global Muslim communities exceeding two billion people. This comprehensive framework provides evidence-based recommendations for medication scheduling, dose optimization, and treatment continuity during Ramadan fasting periods.

    Sheikh Faisal bin Obaid Al Maktoum praised the initiative as embodying “the UAE’s vision for healthcare that harmonizes scientific innovation with compassion and inclusion.” He emphasized the nation’s commitment to developing medical advancements that respect cultural and spiritual traditions while delivering world-class, human-centered care.

    Dr. Vinod Metta, Director of Movement Disorders at King’s Parkinson’s Centre, described the guidelines as “a milestone in the global Parkinson’s community” that balances “medical precision with cultural sensitivity.” The framework enables patients to observe religious practices safely under professional guidance without compromising clinical care.

    Huzaifa Ibrahim of Parkinson’s UAE highlighted the guidelines’ transformative impact, noting they “bring hope and clarity to thousands of Muslims living with Parkinson’s worldwide” while demonstrating that faith and health can coexist harmoniously.

    The multi-center international collaboration involved specialists from Bahrain, Kuwait, the UK, Germany, India, and Australasia. The selection of Mohammed Bin Rashid Library as the launch venue symbolized the initiative’s focus on knowledge-sharing and global exchange of best clinical practices, positioning Dubai as a leading hub for culturally-responsive healthcare innovation.

  • Samsung Galaxy S26 series set for February 25 debut: Here’s everything we expect at Unpacked 2026

    Samsung Galaxy S26 series set for February 25 debut: Here’s everything we expect at Unpacked 2026

    In a landmark initiative for the United Arab Emirates’ healthcare sector, Mediclinic City Hospital in Dubai has inaugurated the nation’s first ‘Tree of Life’ installation. This permanent artistic monument serves as a profound tribute to both deceased organ donors and living individuals who have made the life-altering decision to donate. The unveiling marks a significant step in the UAE’s ongoing efforts to promote organ donation awareness and honor those whose selfless acts have saved countless lives.

    The ‘Tree of Life’ stands as more than just a memorial; it functions as an educational and inspirational centerpiece within the hospital. Its primary objective is to foster a culture of organ donation by visually representing the impact of each donor’s legacy. By creating a physical symbol of gratitude, Mediclinic aims to demystify the donation process and encourage open conversations among patients, families, and healthcare professionals about this critical aspect of modern medicine.

    This initiative aligns with the UAE’s broader National Program for Donation and Transplantation of Human Organs and Tissue, reflecting growing institutional support for transplant medicine. Hospital administrators emphasize that the tree will serve as an enduring reminder of how individual generosity can trigger a cascade of healing, potentially saving up to eight lives through organ donation and enhancing many more through tissue donation.

    The installation arrives at a pivotal moment as healthcare authorities work to address the gap between supply and demand for transplantable organs. By celebrating donors publicly, Mediclinic hopes to normalize donation discussions within Emirati society and contribute to increasing registration rates across the country’s diverse population.

  • Research finds interaction with father, not mother, affects child health

    Research finds interaction with father, not mother, affects child health

    A groundbreaking longitudinal study conducted by Pennsylvania State University researchers has revealed a surprising correlation between paternal parenting behaviors during infancy and children’s long-term cardiovascular health. Published in Health Psychology, the research followed 292 families over seven years, examining three-way interactions among infants, fathers, and mothers at multiple developmental stages.

    The investigation demonstrated that fathers who displayed less attentiveness toward their 10-month-old infants frequently encountered difficulties in cooperative parenting arrangements. These fathers typically exhibited either competitive behaviors with mothers for children’s attention or complete emotional withdrawal from family dynamics. Most significantly, children of these fathers displayed measurable biomarkers of compromised health at age seven, including elevated inflammatory markers and increased blood glucose levels.

    Remarkably, the study found no comparable correlation between maternal parenting behaviors and children’s physiological health outcomes. Dr. Alp Aytuglu, postdoctoral scholar at Penn State’s College of Health and Human Development and study co-author, expressed surprise at these findings: “We naturally anticipated that both parental figures would influence child development, but the data consistently pointed toward paternal behaviors as the determining factor.”

    The research team proposes the “father vulnerability hypothesis” to explain these results, suggesting that fathers demonstrate particular emotional sensitivity to relational stress within the family unit. This heightened reactivity may subsequently influence overall family dynamics and ultimately affect children’s physiological wellbeing. Alternatively, researchers speculate that children’s heightened sensitivity to paternal behavior in group settings might stem from typically spending more one-on-one time with mothers, making father-child interactions in family contexts particularly impactful.

    Independent experts caution that while the findings are compelling, the correlational nature of the study prevents definitive causal conclusions. The relatively homogeneous demographic composition of the study participants—predominantly white, middle-class, two-parent families—also limits immediate generalizability to more diverse populations. Nevertheless, the research represents a significant advancement in understanding how early family dynamics can influence long-term health outcomes, challenging historical assumptions that primarily emphasized maternal influence on child development.

  • From three hours to 30 minutes: New heart procedure in UAE cuts stroke risk by 25%

    From three hours to 30 minutes: New heart procedure in UAE cuts stroke risk by 25%

    The United Arab Emirates has entered a transformative phase in cardiac treatment with the introduction of pulse field ablation (PFA), a groundbreaking medical procedure that significantly enhances atrial fibrillation treatment. This innovative approach, currently being implemented at Al Qassimi Hospital, represents a monumental leap forward in electrophysiological interventions.

    Medical experts describe PFA technology as ushering in “a new era” of cardiac care by dramatically reducing procedural duration from approximately three hours to a mere 30 minutes. The technique specifically addresses atrial fibrillation, recognized globally as the most prevalent heart rhythm disorder. Unlike conventional methods that necessitate general anesthesia, this advanced procedure can be performed using conscious sedation, substantially minimizing patient risk and discomfort.

    Dr. Mohamed Magdy Abbas, Consultant and Head of the EP unit at Al Qassimi Hospital, emphasized the profound clinical implications during discussions at the World Health Expo in Dubai. The Volt system catheter technology enables real-time visualization of heart tissue contact while achieving unprecedented precision in targeting abnormal electrical signals. This specificity has resulted in complication rates plummeting from 7% to just 2%.

    The medical benefits extend far beyond procedural efficiency. This advanced treatment modality demonstrates a remarkable 25% reduction in stroke risk among patients by effectively preventing heart failure progression. Furthermore, recovery timelines have been radically compressed, with studies exploring the feasibility of same-day discharge protocols.

    Post-procedure monitoring incorporates sophisticated subcutaneous chips that continuously track cardiac rhythms, providing clinicians with comprehensive data for optimal patient management. Early outcomes indicate significantly lower recurrence rates compared to traditional radiofrequency and cryo ablation techniques.

    This medical innovation promises substantial improvements in quality of life, disability prevention, and long-term cardiovascular health outcomes. As the technology continues to evolve, UAE healthcare institutions position themselves at the forefront of cardiac care innovation, potentially establishing new global standards in arrhythmia treatment.

  • Global wellness movement elevates sardines as experts call for a reset in metabolic health

    Global wellness movement elevates sardines as experts call for a reset in metabolic health

    In a significant shift within global nutritional guidance, the Medical Wellness Association (MWA) has officially designated 2026 as ‘The Year of the Sardine,’ positioning the humble fish at the forefront of a worldwide metabolic health revolution. This declaration comes amid deteriorating wellness metrics across developed nations, prompting experts to advocate for a fundamental dietary overhaul centered on nutrient-dense, affordable foods.

    MWA President Dr. Christopher Breuleux emphasizes the urgent need to address metabolic dysfunction—a primary driver behind escalating rates of heart disease, diabetes, fatty-liver disease, and certain cancers. The association’s initiative aims to educate consumers globally about the transformative health benefits of nutritionally rich foods, with sardines emerging as an optimal choice.

    James Michael Lafferty, Founding Board Member and Faculty at MWA, clarifies the scientific rationale behind this recommendation: ‘Chronically elevated insulin acts as a storage hormone, prompting the body to accumulate visceral fat around organs when persistently high.’ He identifies conventional low-fat, high-carbohydrate diets as primary contributors to metabolic decline, noting that blood sugar elevation often represents the final stage of decades-long silent damage.

    Sardines offer a powerful nutritional solution to this crisis. They provide high-quality protein and omega-3 fatty acids without carbohydrates, resulting in minimal insulin response. Additionally, they deliver exceptional concentrations of essential vitamins and minerals while ranking among the world’s most cost-effective animal proteins.

    The nutritional value and safety of sardines depend significantly on sourcing and processing methods. Michelle Tiu Lim-Chan, CEO and President of Mega, highlights the importance of origin and freshness: ‘Where the fish comes from and how quickly it’s processed determine its ultimate nutritional value.’ Her company’s ‘catch to can in 12 hours’ protocol, utilizing pristine South Pacific waters, has earned Mega the world’s sole ‘Superfood’ certification for sardines from MWA.

    Market projections indicate substantial growth for the sardine industry, with anticipated acceleration from 7.5% to over 10% annually beginning in 2026. This surge reflects growing scientific validation and consumer awareness about metabolic health management through dietary choices.

    This movement represents more than nutritional trend—it embodies a fundamental rethinking of lifestyle disease management. As Lafferty concludes: ‘Type two diabetes is not a lifelong condition by default. With discipline, it can be reversed through strategic dietary intervention.’ Once considered mere pantry staples, sardines now stand at the intersection of scientific research, economic accessibility, and global wellness advancement.

  • CellSave Arabia qualified by Gilead and Kite to support advanced cell therapy for lymphoma patients

    CellSave Arabia qualified by Gilead and Kite to support advanced cell therapy for lymphoma patients

    In a significant advancement for cancer care in the Middle East, CellSave Arabia has achieved qualification from biotechnology leaders Gilead and Kite to deliver specialized cell storage services for lymphoma treatments across the United Arab Emirates. This strategic collaboration establishes new pathways for patients requiring advanced cellular therapies, particularly CAR T-cell treatments that represent a breakthrough in oncology care.

    As the region’s premier private stem cell laboratory operating under CSG.BIO, CellSave Arabia brings state-of-the-art biobanking capabilities to this partnership. The company maintains internationally recognized accreditations including AABB, FDA, and ISO 2038 certifications, ensuring compliance with global standards for cellular preservation. This infrastructure positions the organization as a critical component in the CAR T-cell treatment process, where secure handling and storage of biological material is paramount.

    Kite, a Gilead subsidiary acquired in 2017, stands as a global pioneer in cell therapy innovation. The company has developed transformative treatments including YESCARTA and TECARTUS, which have demonstrated remarkable efficacy against certain lymphoma variants. To date, more than 32,000 patients worldwide have received Kite’s CAR T-cell therapies through over 555 authorized treatment centers. Within the UAE, the company currently maintains two approved CAR T-cell therapies across four medical indications.

    Alia Abdel-Razeq, Chief Operating Officer of CellSave Arabia, emphasized the patient-centric nature of this collaboration. “Our fundamental mission revolves around placing patients at the core of every innovation we pursue,” she stated. “This partnership enables us to support lymphoma patients with unprecedented levels of precision, safety, and care while maintaining the highest preservation standards for cellular materials.”

    Eslam Khedr, Head of Oncology Regional Headquarters for Gilead and Kite Middle East, highlighted the individualized nature of CAR T therapy. “This approach represents a truly personalized treatment modality with curative intent for patients confronting difficult-to-treat blood cancers,” Khedr explained. “Meeting patient and healthcare professional needs requires robust treatment delivery infrastructure, which we’ve developed through one of the world’s most extensive in-house manufacturing networks.”

    This collaboration underscores the UAE’s emerging role as a regional hub for next-generation biomedical innovation and scientific collaboration. By combining CellSave Arabia’s specialized biobanking expertise with Gilead and Kite’s therapeutic leadership, the partnership aims to streamline treatment pathways, enhance accessibility to advanced cancer therapies, and ultimately improve outcomes for patients battling hematological malignancies across the Middle East.

  • Moderna says FDA refuses its application for new mRNA flu vaccine

    Moderna says FDA refuses its application for new mRNA flu vaccine

    In a significant regulatory development, Moderna announced Tuesday that the U.S. Food and Drug Administration has declined to review the company’s application for an innovative mRNA-based influenza vaccine. The decision represents the latest indication of intensified FDA oversight under Health Secretary Robert F. Kennedy Jr., who has consistently expressed skepticism toward mRNA technology both before and after assuming his current position.

    The FDA issued a ‘refusal-to-file’ letter citing concerns about Moderna’s clinical trial design, which involved 40,000 participants comparing the new vaccine against a standard flu shot. While the study demonstrated superior efficacy in adults aged 50 and older, FDA vaccine director Dr. Vinay Prasad determined the application lacked an ‘adequate and well-controlled trial’ because it didn’t compare the vaccine to ‘the best-available standard of care in the United States at the time of the study.’

    According to Moderna, FDA officials under the Biden administration had provided 2024 guidance indicating that while another brand specifically recommended for seniors would be preferable for participants aged 65 and older, the company’s chosen standard-dose vaccine remained acceptable. Moderna proceeded with the original study design with FDA’s conditional approval.

    The company emphasized that the FDA identified no specific safety or efficacy concerns with their product and noted they had submitted additional data from a separate trial comparing the vaccine against a licensed high-dose shot for elderly patients. Moderna CEO Stephane Bancel stated the decision ‘does not further our shared goal of enhancing America’s leadership in developing innovative medicines.’

    This regulatory action occurs against a backdrop of significant policy shifts under Kennedy’s leadership, including the rollback of COVID-19 shot recommendations, additional warnings for leading mRNA COVID vaccines, and the removal of administration critics from FDA advisory panels. Kennedy previously announced the cancellation of over $500 million in contracts and funding for mRNA vaccine development.

    The refusal marks a departure from decades of FDA practice allowing vaccine manufacturers to update annual flu shots based on immune response data rather than long-term efficacy studies. Prasad’s internal memo last year indicated this streamlined approach would no longer be permitted, prompting criticism from more than a dozen former FDA commissioners.

    Moderna has requested an urgent meeting with the FDA while pursuing regulatory approval for the vaccine in Europe, Canada, and Australia.

  • Dubai introduces region’s first system for 15-minute health inspections for ships

    Dubai introduces region’s first system for 15-minute health inspections for ships

    Dubai has pioneered a groundbreaking maritime health inspection system that dramatically reduces vessel clearance times from two hours to just 15 minutes. The Health Inspection Management Application (HIMA), unveiled at the World Health Expo, represents the region’s first integrated digital solution for combating cross-border health threats through advanced automation and data analytics.

    The innovative system operates through pre-arrival digital integration, where ship tracking technologies provide comprehensive data including the vessel’s last ten ports of call and medical logs before docking. According to Ali Thani Al Mehairi, Consultant at Dubai Health Authority’s Public Health Protection Department, this preemptive data collection enables inspectors to conduct risk assessments prior to physical arrival, transforming the inspection process into a verification procedure rather than a discovery mission.

    HIMA’s intelligent alert system automatically flags vessels with medical incidents exceeding 3% of personnel, prioritizing high-risk ships while expediting clearance for others. The completely digitized workflow eliminates traditional paperwork, allowing ship agents to submit requests and receive approvals through a seamless online platform.

    The phased implementation commenced immediately at Port Rashid and Al Shindagha Port, with comprehensive coverage across all Dubai maritime ports scheduled by late 2026. Authorities confirmed expansion plans for land border crossings by 2027 and are exploring adaptations for air travel security.

    Dr. Alawi Alsheikh-Ali, Director General of DHA, characterized HIMA as “a qualitative leap in the emirate’s public health framework” that reinforces Dubai’s leadership in deploying digital solutions for community safety. The system’s Arabic namesake, meaning “securing your borders,” reflects its core mission of strengthening public health defenses while ensuring uninterrupted commercial operations through smart data utilization and automated risk management.

  • Al Zahra Hospital Dubai introduces advanced photon-counting CT technology

    Al Zahra Hospital Dubai introduces advanced photon-counting CT technology

    Al Zahra Hospital Dubai has achieved a groundbreaking milestone in medical imaging by deploying the NAEOTOM Alpha photon-counting computed tomography system from Siemens Healthineers. This state-of-the-art installation represents the first implementation of this revolutionary technology in the United Arab Emirates, significantly advancing the hospital’s diagnostic capabilities.

    Unlike conventional CT systems that utilize energy-integrating detectors, photon-counting technology operates by detecting and quantifying individual X-ray photons. This innovative approach generates exceptionally high-resolution images with substantially reduced noise interference while simultaneously enabling spectral imaging during every scan. The system’s sophisticated architecture permits superior differentiation between various biological materials including iodine, calcium, and soft tissues within a single imaging session, eliminating the necessity for additional specialized protocols.

    A particularly noteworthy advantage of this cutting-edge technology is its ability to deliver superior image quality while reducing radiation exposure by up to 30% compared to traditional CT systems. This radiation reduction proves especially beneficial for pediatric patients, cardiac imaging cases, and individuals requiring recurrent follow-up examinations. Furthermore, the system incorporates contrast dose optimization features that provide significant advantages for patients with renal impairments or other contraindications to contrast agents.

    In cardiovascular applications, the photon-counting CT demonstrates exceptional capability in imaging challenging coronary cases that previously posed diagnostic difficulties. Patients with extensive coronary calcification, elevated body mass indices, or higher heart rates can now be evaluated with unprecedented clarity. The technology’s enhanced spatial resolution enables more accurate assessment of coronary artery disease and facilitates improved treatment planning strategies.

    The system’s rapid acquisition speed and artificial intelligence-integrated software support make it particularly valuable in neurovascular emergencies. For stroke patients, the technology enables comprehensive evaluation of cerebral vasculature and perfusion within critical timeframes, potentially accelerating life-saving clinical decisions.

    Beyond cardiology and neurology, the technology offers substantial benefits across multiple medical specialties including orthopedics, oncology, and abdominal imaging. The system provides exceptional visualization of complex fractures, orthopedic implants, malignant tumors, and intricate lesions, often accomplishing comprehensive assessment through a single scanning procedure.

    Dr. Amr Aly, Chief Medical Officer at Al Zahra Hospital Dubai, emphasized the strategic importance of this advancement: ‘This technology deployment exemplifies our commitment to integrating world-class diagnostic solutions that enhance both clinical accuracy and patient safety. The photon-counting CT system represents a paradigm shift in medical imaging that will benefit numerous patient populations across our healthcare ecosystem.’

    This technological implementation aligns with Dubai’s broader vision to establish itself as a preeminent global healthcare destination, reinforcing the emirate’s position as a regional center for specialized medical care and cutting-edge technological innovation in the healthcare sector.

  • How Dubai uses VR headsets to help kids relax during treatment

    How Dubai uses VR headsets to help kids relax during treatment

    Dubai Health is spearheading a transformative approach to healthcare through its newly established Centre for Innovation and Technology, deploying cutting-edge technologies to enhance patient experiences and clinical outcomes. The 2,000-square-meter innovation hub serves as the core of this initiative, focusing on converting healthcare challenges into practical, technology-driven solutions.

    A flagship program utilizes virtual reality (VR) headsets to alleviate anxiety and pain in pediatric patients undergoing frequent blood procedures, such as those at the thalassemia center. According to Yacine Hadjiat, Director of the Centre, clinicians reported significant anxiety in young patients during cannulation. The immersive VR experience effectively distracts children, reducing their focus on medical needles and creating a more relaxed treatment environment. This program has already been trialed on over 100 patients and is expanding to emergency and mental health departments across multiple hospitals.

    Beyond VR applications, the innovation center is executing a comprehensive redesign of patient journeys. Through collaboration with clinicians, staff, and medical students, more than 90 improvement projects have been identified to address pain points from registration to waiting times. Enhancements include streamlined digital access via the Dubai Health app, where patients pre-upload information to facilitate seamless clinic visits, and physical redesigns of clinical spaces to reduce stress.

    The center operates through four specialized laboratories focusing on human-centered design, data and artificial intelligence, sensors and wearables, and extended reality technologies.

    Looking toward the future, Dubai Health is advancing a groundbreaking research initiative named Pain Detect, funded by the Dubai Future Foundation’s 2024 RDI grant. This project aims to develop an AI-powered wearable system that objectively measures pain through physiological signals, moving beyond subjective patient descriptions. This technology could revolutionize care for non-communicative patients, including children and intensive care occupants, establishing a new global standard in pain management.